ZGNX - Zogenix's Medication For Dravet Syndrome Likely Delayed 12-15 Months
In business and in particular drug development, rarely do things go as planned. Zogenix (ZGNX) is a pharmaceutical company developing therapies for people living with serious and life-threatening rare central nervous system (CNS') conditions. Zogenix's lead product candidate Fintepla is low-dose fenfluramine for the treatment of seizures associated with two rare and catastrophic forms of childhood-onset epilepsy: Dravet syndrome and Lennox-Gastaut syndrome (LGS').
In February 2019, Zogenix completed the submission of a new drug application (NDA') with the FDA and submitted a marketing authorization application (MAA') to the European Medicines Agency (EMA'). The